Obesity Week 2025 Medications Eloralintide (LY 3841136) Amylin Receptor Activator MedChemExpress PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar In early studies, a new drug under investigation called eloralintide helped some adults lose nearly 50 pounds in under a year and it's not a GLP 1: https: bit.ly 43nPJnS 2025 ADA Highlights: A New Era for GLP 1 Therapies in Obesity and Diabetes Biopharma PEG Eloralintide Phase 2 Paper Out: 20% weight loss after 48 weeks : r Zepbound